Specify a stock or a cryptocurrency in the search bar to get a summary
Mabion S.A.
MABMabion S.A., a biotechnology company, engages in the development of various biotech drugs based on monoclonal antibody technology in Poland. The company develops, produces, and sells medicines for the treatment of neoplastic, autoimmune, metabolic, and neurological diseases. Its products include MabionCD20 and MabionHER2. Mabion S.A. was founded in 2007 and is based in Konstantynów Lódzki, Poland. Address: ul. gen. Mariana Langiewicza 60, Konstantynów Lódzki, Poland, 95-050
Analytics
WallStreet Target Price
54.11 PLNP/E ratio
19.4921Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures MAB
Dividend Analytics MAB
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History MAB
Stock Valuation MAB
Financials MAB
Results | 2019 | Dynamics |